Journal Article Review Epublish 1 citation
PubMed: 40004173 DOI: 10.3390/ijms26041711
Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present.
Int J Mol Sci 26(4)
Authors: Jacob Naman, Nirja Shah, Benjamin M Heyman
Affiliations
- Department of Medicine, UC San Diego Health, La Jolla, CA 92037, USA.
- UCSD School of Medicine, La Jolla, CA 92037, USA.
- Department of Medicine, Division of Regenerative Medicine, UC San Diego Health, La Jolla, CA 92037, USA.
Abstract
Antibody therapies are a crucial component of modern lymphoid malignancy treatment and an exciting area of active research. We performed a review of modern antibody therapies used in the treatment of lymphoid malignancies, with an emphasis on landmark studies and current directions. We describe the indications for rituximab, obinutuzumab, ADCs, and bispecific antibody therapies. Finally, we summarize early data from ongoing trials on emerging novel therapy combination regimens and discuss the role of machine learning in future therapy development.
MeSH
Neoplasms, Rituximab, Therapeutics, Epcoritamab
Cited by
- Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma? Cancers (Basel), 2025
- Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma. Cancers (Basel), 2025
- Rare Primary Diffuse Large B-Cell Lymphoma Confined to Bone Marrow: Features and Prognosis. Oncol Res, 2025